Evofem Biosciences (EVFM) Misses Q4 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Evofem Biosciences (EVFM) Misses Q4 EPS by 17c

Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

March 1, 2019 6:00 AM EST

SAN DIEGO, March 1, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical company, today reported financial results for the three- and twelve- month periods ended December 31, 2018. Fourth quarter and recent highlights include:

Successfully completed AMPOWER, the second Phase 3 trial of Amphora for non-hormonal birth control, with positive top-line AMPOWER results positioning Evofem to re-submit the Amphora New Drug Application (NDA) in the second quarter of 2019; and, Patient enrollment in AMPREVENCE, the Phase 2b clinical trial evaluating the ability of... More